James Yao

James Yao at MD Anderson Cancer Center led the pivotal RADIANT-3 trial establishing everolimus in pancreatic NETs and has been a key investigator across the RADIANT trial series for NETs of various primary sites. His research has clarified the molecular underpinnings of mTOR activation in NETs and its therapeutic implications. He has advanced the understanding of NET natural history and prognostication using molecular markers. He is among the most influential clinical investigators in the global NET research community.